Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Vaccine experts say Moderna (MRNA) didn’t produce data critical to assessing Covid-19 vaccine - STAT
May 19, 2020 2:56 PM EDTVaccine experts say Moderna (NASDAQ: MRNA) didnt produce data critical to assessing Covid-19 vaccine - STAT
... MoreModerna (MRNA) Announces Proposed $1.25 Billion Public Offering of Shares of Common Stock
May 18, 2020 4:18 PM EDTModerna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has commenced an underwritten public offering of $1.25 billion in shares of common stock. In addition, Moderna expects to grant the underwriters a 30-day option to purchase up... More
